Pretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy
Top Cited Papers
Open Access
- 27 July 2005
- journal article
- research article
- Published by American Medical Association (AMA)
- Vol. 294 (4) , 440-447
- https://doi.org/10.1001/jama.294.4.440
Abstract
The impact of prostate-specific antigen (PSA) screening on mortality remains under study,1,2 but since the introduction of PSA testing the presentation of prostate cancer has shifted toward younger men with less aggressive and smaller-volume disease.3,4 Concomitant with stage migration the median PSA level at presentation has also decreased such that PSA levels greater than 10.0 ng/mL at diagnosis have become infrequent.5 Moreover, benign prostatic hypertrophy increases serum PSA levels and is commonly seen in men of prostate cancer–bearing age. As a result, the prognostic significance of any single value of PSA below 10.0 ng/mL is becoming more limited.Keywords
This publication has 0 references indexed in Scilit: